Clinical Trials Browser

Hematologic Neoplasms

Advanced Malignancies

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Renal Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Endometrial Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Advanced Endometrial Cancer

Endometrial Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Thyroid Neoplasms

Carcinoma, Hepatocellular, Neoplasms

Differentiated Thyroid Cancer (DTC)

Clinical Trials

MK-3475-587

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

MK-6482-043

LEAP-012

MK-6482-012

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

MK-6482-011

EMERALD-3

CheckMate 9DW

MK-3475-775

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

CLEAR

LEAP-007

LEAP-003

LEAP-002

LEAP-006

LEAP-011

MK-7902-017

LEAP-001

LEAP-003

MK-7902-014

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

LEAP-001

LEAP-006

LEAP-008

LEAP-007

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

SELECT

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China